News for January 2017

News Archive

Global Kinetics Corporation Joins Quest to Predict Parkinson’s Global Kinetics Corporation Joins Quest to Predict Parkinson’s

Australian medical technology company, Global Kinetics Corporation, is proud to be working with neurologist and Parkinson’s UK-funded researcher, Dr Alastair Noyce from the Institute of Neurology, University College London, to help spot early warning signs of Parkinson’s.

The Current issue of “The view from here” is concerned with the Best of 2016. The Current issue of “The view from here” is concerned with the Best of 2016.

The topic of this month’s newsletter from Drug Discovery Today is “The Best of 2016”.

AstraZeneca shares world-leading world’s most advanced drug discovery robot through Open Innovation AstraZeneca shares world-leading world’s most advanced drug discovery robot through Open Innovation

NiCoLA-B, the world’s most advanced drug discovery robot, is teaming up with scientists from Cancer Research UK (CRUK) and the Medical Research Council (MRC), through AstraZeneca’s Open Innovation research collaboration programme. The new robot, which can test up to 300,000 compounds a day, is designed to make drug discovery smarter, faster and cheaper. It can work three times more quickly than previous drug discovery robots and can sense and adapt to the presence of its human workmates. This means it can share their workspace without protective guarding.

New insights in genetic defect allow prevention of fatal illnesses in children New insights in genetic defect allow prevention of fatal illnesses in children

A team of scientists led by prof. Adrian Liston (VIB–KU Leuven) and prof. Isabelle Meyts (UZ Leuven – KU Leuven) were able to characterize a new genetic immunodeficiency resulting from a mutation in a gene named STAT2. This mutation causes patients to be extremely vulnerable to normally mild childhood illnesses such as rotavirus and enterovirus. Prof. Liston’s comprehensive analysis of the genetic defect allows clinicians to provide children with the proper therapies before illnesses prove fatal. The findings of the research have been published in the Journal of Allergy and Clinical Immunology.

MRC Technology, Cancer Research UK and Cancer Research Technology Collaborate To Focus On Cancer Immunotherapies MRC Technology, Cancer Research UK and Cancer Research Technology Collaborate To Focus On Cancer Immunotherapies

Cancer Research UK, Cancer Research Technology and MRC Technology are joining forces to identify and validate novel drug discovery targets that could lead to new immunotherapy treatments.

MRC Technology Centre for Diagnostics Development relocates as part of £7million investment to expand diagnostics research capability MRC Technology Centre for Diagnostics Development relocates as part of £7million investment to expand diagnostics research capability

Move to Nine, Edinburgh BioQuarter offers increase in laboratory and office space

Benzodiazepines and related drugs increase stroke risk among persons with Alzheimer’s disease Benzodiazepines and related drugs increase stroke risk among persons with Alzheimer’s disease

The use of benzodiazepines and benzodiazepine-like drugs was associated with a 20 per cent increased risk of stroke among persons with Alzheimer’s disease, shows a recent study from the University of Eastern Finland. Benzodiazepines were associated with a similar risk of stroke as benzodiazepine-like drugs.